Advertisement

Comparison of Adverse Cardiovascular Events and Bleeding Complications of Loading Dose of Clopidogrel 300 mg Versus 600 mg in Stable Patients Undergoing Elective Percutaneous Intervention (from the CADICE Study)

      In large clinical trials enrolling patients with acute coronary syndromes, a high loading dose of clopidogrel (600 mg) has been found to be more effective compared to a low loading dose (300 mg). However, the applicability of these data to stable patients who undergo elective percutaneous coronary intervention is still unclear. A total of 400 patients who underwent elective PCI were prospectively randomized to receive either 600 mg (n = 200) or 300 mg (n = 200) of clopidogrel, followed by a daily maintenance dose of 75 mg. The primary end point was the presence of major adverse cardiovascular events (combined death, myocardial infarction, acute neurologic event, stent thrombosis, and need for percutaneous or surgical revascularization of the target vessel) during hospitalization and at 30 days. The secondary end point was periprocedural vascular complications, major bleeding, and cardiac enzyme elevation. There were no differences in the primary end point among the groups immediately after the procedure (3.5% of patients in the 300-mg group vs 4.5% of those in the 600-mg group, p = 0.799) or at 30 days (6% vs 5%, respectively, p = 0.826). The rates of periprocedural vascular complications (2.5% vs 3%, respectively, p = 1.00), bleeding complications (9% vs 8.5%, respectively, p = 1.00), and cardiac enzyme elevation (11% vs 15.5%, respectively, p = 0.317) were similar between the 2 groups. In conclusion, adverse cardiovascular events and bleeding complications during the initial hospitalization and at 30-day follow-up were similar when a 600-mg loading dose of clopidogrel was used compared to the conventional dose of 300 mg.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bertrand M.E.
        • Rupprecht H.J.
        • Urban P.
        • Gershlick A.H.
        Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS).
        Circulation. 2000; 102: 624-629
        • Patti G.
        • Colonna G.
        • Pasceri V.
        • Pepe L.L.
        • Montinaro A.
        • Di Sciascio G.
        Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty) study.
        Circulation. 2005; 111: 2099-2106
        • Fefer P.
        • Hod H.
        • Hammerman H.
        • Segev A.
        • Beinart R.
        • Boyko V.
        • Behar S.
        • Matetzky S.
        Usefulness of pretreatment with high-dose clopidogrel in patients undergoing primary angioplasty for ST-elevation myocardial infarction.
        Am J Cardiol. 2009; 104: 514-518
        • Lotrionte M.
        • Biondi-Zoccai G.G.
        • Agostoni P.
        • Abbate A.
        • Angiolillo D.J.
        • Valgimigli M.
        • Moretti C.
        • Meliga E.
        • Cuisset T.
        • Alessi M.C.
        • Montalescot G.
        • Collet J.P.
        • Di Sciascio G.
        • Waksman R.
        • Testa L.
        • Sangiorgi G.
        • Laudito A.
        • Trevi G.P.
        • Sheiban I.
        Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention.
        Am J Cardiol. 2007; 100: 1199-1206
        • Pache J.
        • Kastrati A.
        • Mehilli J.
        • Gawaz M.
        • Neumann F.J.
        • Seyfarth M.
        • Hall D.
        • Braun S.
        • Dirschinger J.
        • Schomig A.
        Clopidogrel therapy in patients undergoing coronary stenting: value of a high-loading-dose regimen.
        Catheter Cardiovasc Interv. 2002; 55: 436-441
        • Abuzahra M.
        • Pillai M.
        • Caldera A.
        • Hartley W.B.
        • Gonzalez R.
        • Bobek J.
        • Dokainish H.
        • Lakkis N.
        Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after percutaneous coronary intervention using drug-eluting stents.
        Am J Cardiol. 2008; 102: 401-403
        • Gurbel P.A.
        • Bliden K.P.
        • Hayes K.M.
        • Yoho J.A.
        • Herzog W.R.
        • Tantry U.S.
        The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting.
        J Am Coll Cardiol. 2005; 45: 1392-1396
        • King III, S.B.
        • Smith Jr, S.C.
        • Hirshfeld Jr, J.W.
        • Jacobs A.K.
        • Morrison D.A.
        • Williams D.O.
        • Feldman T.E.
        • Kern M.J.
        • O'Neill W.W.
        • Schaff H.V.
        • Whitlow P.L.
        • Adams C.D.
        • Anderson J.L.
        • Buller C.E.
        • Creager M.A.
        • Ettinger S.M.
        • Halperin J.L.
        • Hunt S.A.
        • Krumholz H.M.
        • Kushner F.G.
        • Lytle B.W.
        • Nishimura R.
        • Page R.L.
        • Riegel B.
        • Tarkington L.G.
        • Yancy C.W.
        2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines.
        J Am Coll Cardiol. 2008; 51: 172-209
        • Silber S.
        • Albertsson P.
        • Aviles F.F.
        • Camici P.G.
        • Colombo A.
        • Hamm C.
        • Jorgensen E.
        • Marco J.
        • Nordrehaug J.E.
        • Ruzyllo W.
        • Urban P.
        • Stone G.W.
        • Wijns W.
        Percutaneous coronary interventions.
        Kardiol Pol. 2005; 63 ([article in Polish]): 265-323
        • Wolfram R.M.
        • Torguson R.L.
        • Hassani S.E.
        • Xue Z.
        • Gevorkian N.
        • Pichard A.D.
        • Satler L.F.
        • Kent K.M.
        • Waksman R.
        Clopidogrel loading dose (300 versus 600 mg) strategies for patients with stable angina pectoris subjected to percutaneous coronary intervention.
        Am J Cardiol. 2006; 97: 984-989
        • Karpatkin S.
        Heterogeneity of human platelets.
        J Clin Invest. 1969; 48: 1083-1087
        • Yilmaz M.B.
        • Cihan G.
        • Guray Y.
        • Guray U.
        • Kisacik H.L.
        • Sasmaz H.
        • Korkmaz S.
        Role of mean platelet volume in triagging acute coronary syndromes.
        J Thromb Thrombolysis. 2008; 26: 49-54
        • Karpatkin S.
        Heterogeneity of human platelets.
        J Clin Invest. 1969; 48: 1073-1082
        • Martin J.F.
        • Trowbridge E.A.
        • Salmon G.
        • Plumb J.
        The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration.
        Thromb Res. 1983; 32: 443-460

      Linked Article